Biotricity, Inc. (NASDAQ: BTCY) Q4 2025 Earnings | 07/18/2025

About this video

Biotricity, Inc. (NASDAQ: BTCY) delivered its Q4 2025 results on July 18, 2025, capping a transformative fiscal year with substantial revenue growth, improved margins, and a milestone achievement of positive adjusted EBITDA for the first time in company history. For the quarter ended March 31, 2025, Biotricity reported revenue of $3.7 million—a 16.5% year-over-year increase driven by recurring Technology-as-a-Service (TaaS) fees and the expansion of its Cardiac AI Cloud platform. Full-year revenue advanced 14.3% to $13.8 million, reflecting a strong trajectory in subscription-based diagnostics and remote monitoring services. Gross margin for Q4 2025 expanded to 80.4%, up from 71.5% a year earlier, as ongoing automation, proprietary AI integration, and increased technology revenue offset cost pressures. Annual gross margin also improved sharply to 76.6%. Operating expenses for the fiscal year fell 24.5% to $13 million, reflecting disciplined cost controls and operational efficiencies across the business. The company recorded a reduced net loss of $2.0 million (or $0.08 per share) in Q4 2025, compared to a $4.4 million loss in the prior-year period. For the year, net loss improved 20% to $11.9 million (or $0.56 per share). Adjusted EBITDA turned positive in Q4 at $438,000 (or $0.017 per share), underscoring Biotricity’s successful path to breakeven status. Strategically, Biotricity entered new partnerships with Group Purchasing Organizations (GPOs) accessing 90% of U.S. hospitals, strengthened its pipeline for value-based care payor contracts, and advanced its FDA application for an AI-driven cardiac clinical model. Growth was further supported by robust client retention, a broadened product portfolio, and market expansion initiatives—including progress in international markets due to emerging strategic alliances. CEO Dr. Waqaas Al-Siddiq highlighted that Biotricity’s cloud platform, automation, and AI investments are driving operational leverage and setting the stage for sustainable profitability. Margin gains, the shift toward positive adjusted EBITDA, and the company’s position at the forefront of digital health monitoring and diagnostics signal strong momentum heading into fiscal 2026. About Inside Ticker: For detailed financial coverage, market analysis, and the latest news on Biotricity, Inc. (NASDAQ: BTCY) and other digital health innovators, follow Inside Ticker and visit InsideTicker.com for expert insights and real-time updates. Hashtags: #Biotricity #BTCY #Q42025 #Earnings #FinancialResults #RevenueGrowth #AdjustedEBITDA #DigitalHealth #RemoteMonitoring #AI #CardiacCare #GrossMargin #TechAsAService #OperationalExcellence #HealthcareInnovation #GPO #HealthcareAI #Profitability #InsideTicker #InvestorUpdate #Q4Results #BusinessUpdate #Diagnostics #SubscriptionRevenue #HealthTech #MarketExpansion #FDA #CEOUpdate #HospitalSolutions #USHealthcare #CloudPlatform